Patents Assigned to AstraZeneca AB
  • Patent number: 11000525
    Abstract: There are disclosed certain 1-[2-(aminomethyl)benzyl]-2-thioxo-1,2,3,5-tetrahydro-4H-pyrrolo[3,2-d]pyrimidin-4-one compounds of formula (I), and pharmaceutically acceptable salts thereof, together with compositions containing them and their use in therapy. The compounds are inhibitors of the enzyme MPO and are thereby particularly useful in the treatment or prophylaxis of cardiovascular disorders such as heart failure and coronary artery disease related conditions.
    Type: Grant
    Filed: June 15, 2018
    Date of Patent: May 11, 2021
    Assignee: ASTRAZENECA AB
    Inventors: Tord Bertil Inghardt, Petra Johannesson, Ulrik Jurva, Erik Michaelsson, Eva-Lotte Lindstedt-Alstermark, Nicholas Tomkinson, Jeffrey Paul Stonehouse, Li-Ming Gan
  • Patent number: 11001589
    Abstract: The present application relates to novel compounds of formula (I) to their utility in treating and/or preventing clinical conditions including cardiovascular diseases (CVD), to methods for their therapeutic use, to pharmaceutical compositions containing them and to processes for preparing such compounds.
    Type: Grant
    Filed: October 30, 2019
    Date of Patent: May 11, 2021
    Assignee: ASTRAZENECA AB
    Inventors: Johan Olof Broddefalk, Hans Fredrik Emtenâs, Kenneth Lars Granberg, Malin Anita Lemurell, Daniel Tor Pettersen, Alleyn Thomas Plowright, Lars Johan Andreas Ulander
  • Publication number: 20210130901
    Abstract: Biomarkers for the treatment of pathological conditions associated with the PI3K pathway, such as cancer, and methods of using inhibitors of upstream components of the PI3K pathway, such as PI3K-? inhibitors or AKT inhibitors, are described. In particular, there are described biomarkers for patient selection in the treatment of cancer, as well as methods of therapeutic treatment, diagnostic kits and methods of detection, wherein cancers that possess a mutation in an upstream component of the PI3K pathway (such as the PIK3CA gene and/or the AKT gene), and a wild-type MAP3K1 gene and MAP2K4 gene, are more likely to respond favourably to treatment with inhibitors of upstream components of the PI3K pathway.
    Type: Application
    Filed: September 16, 2016
    Publication date: May 6, 2021
    Applicant: ASTRAZENECA AB
    Inventors: Alvaro AVIVAR VALDERAS, Francisco Humberto CRUZALEGUI, Kevin HUDSON, Robert Kenneth McEWEN
  • Patent number: 10994082
    Abstract: An inhaler for delivery of a medicament by inhalation is disclosed. The inhaler comprises a dispensing mechanism, the dispensing mechanism being configured to dispense a dose of medicament on actuation. The inhaler further comprises a dose counting mechanism comprising a counter and a translating member. The translating member comprises a pawl. The counter comprises a first count wheel, a second count wheel and an intermediate wheel engaged with the second count wheel and in selective engagement with the first count wheel. When the inhaler is fired to dispense a dose of medicament, the dispensing mechanism moves the translating member in a substantially linear direction. The pawl thus rotates the first count wheel, and as the first count wheel rotates, the intermediate wheel is selectively engaged thereby selectively rotating the second count wheel to count the doses of the inhaler.
    Type: Grant
    Filed: September 12, 2018
    Date of Patent: May 4, 2021
    Assignee: ASTRAZENECA AB
    Inventors: Simon Christopher Berry, Jonas Christiansen, Svend Erik Elgaard, Esben W. Johansen, Claus Schmidt Moller, Jorgen Rasmussen, Henrik Hougaard Vilstrup, William Richard Treneman
  • Publication number: 20210122735
    Abstract: Disclosed are intermediates and methods of synthesizing Compound 1.
    Type: Application
    Filed: March 29, 2018
    Publication date: April 29, 2021
    Applicant: ASTRAZENECA AB
    Inventors: Craig Robert STEWART, Simon HARDY, Andrew STARK, Alexander HIRD, Qing YE, Xiaolan ZHENG, Cati FERRAR, Jan KOEK, Debasis HAZRA
  • Patent number: 10988445
    Abstract: The present specification provides a compound of formula (I): or a pharmaceutically acceptable salt thereof; a process for preparing such a compound; and to the use of such a compound in the treatment of an ROR? and/or ROR?t mediated disease state.
    Type: Grant
    Filed: November 25, 2019
    Date of Patent: April 27, 2021
    Assignee: AstraZeneca AB
    Inventors: Frank Narjes, Roine Ingemar Olsson, Stefan Von Berg, Sarah Lever
  • Patent number: 10973836
    Abstract: The present disclosure is directed to methods of treating patients with heart failure with reduced ejection fraction (HFrEF), with and without Type 2 diabetes, with an SGLT2 inhibitor, such as dapagliflozin. The methods disclosed herein can reduce the risk of a composite outcome of a first episode of worsening heart failure (hospitalization for heart failure or an urgent heart failure visit) or death from cardiovascular causes. Each of the three components of this composite outcome can also be reduced, as well as the total number of heart failure hospitalizations and deaths from cardiovascular causes. SGLT2 inhibitors, such as dapagliflozin, can also reduce a worsening of heart failure symptoms. The methods disclosed herein can also improve heart failure symptoms, health status, and quality of life.
    Type: Grant
    Filed: March 9, 2020
    Date of Patent: April 13, 2021
    Assignee: ASTRAZENECA AB
    Inventor: Anna Maria Langkilde
  • Patent number: 10961241
    Abstract: The specification relates to compounds of Formula (I): and to pharmaceutically acceptable salts thereof, to processes and intermediates used for their preparation, to pharmaceutical compositions containing them and to their use in the treatment of cell proliferative disorders.
    Type: Grant
    Filed: January 28, 2020
    Date of Patent: March 30, 2021
    Assignee: AstraZeneca AB
    Inventors: Bernard Christophe Barlaam, Daniel Hillebrand O'Donovan, Samantha Jayne Hughes, Thomas Andrew Moss, Johannes Wilhelmus Maria Nissink, James Stewart Scott, Bin Yang
  • Patent number: 10961236
    Abstract: Disclosed herein is the compound (S)-2-(1-cyclopropylethyl)-5-(4-methyl-2-((6-(2-oxopyrrolidin-1-yl)pyridin-2-yl)amino)thiazol-5-yl)-7-(methylsulfonyl)isoindolin-1-one of the following structure: and/or pharmaceutically acceptable salts and/or pharmaceutical compositions thereof, which inhibit phosphatidylinositol 3-kinase (PI3K) activity.
    Type: Grant
    Filed: September 21, 2017
    Date of Patent: March 30, 2021
    Assignee: AstraZeneca AB
    Inventors: Matthew Perry, Christian Tyrchan, Konstantinos Karabelas, Antonios Nikitidis, Mickael Mogemark, Jens Petersen, Peter Bold, Ulf Borjesson
  • Patent number: 10961228
    Abstract: Disclosed herein are compounds of Formula (I), and pharmaceutically acceptable salts thereof, wherein R1-R8 have any of the meanings defined herein. Also disclosed are pharmaceutical compositions comprising compounds of Formula (I) and methods of using the same.
    Type: Grant
    Filed: January 16, 2018
    Date of Patent: March 30, 2021
    Assignee: ASTRAZENECA AB
    Inventors: Karl Magnus Nilsson, Annika Birgitta Margareta Astrand, Anna Ingrid Kristina Berggren, Johan R. Johansson, Matti Juhani Lepisto, Sameer Pralhad Kawatkar, Qibin Su, Jason Grant Kettle
  • Patent number: 10957435
    Abstract: A pharmaceutical company may employ a computer system that is configured to train a machine learning model for predicting a next time in the future at which a given type of treatment decision is likely to be made for a patient, use the trained machine learning model to analyze anonymized patient data for patients treated by a given health care provider (HCP) in order to predict a next time in the future at which the given HCP is likely to make a given type of treatment decision for at least one patient, and then responsively generate a trigger alert suggesting that the given HCP be visited prior to the predicted next time to deliver a message related to the given type of treatment decision, which may in turn be delivered to a target of the trigger alert.
    Type: Grant
    Filed: August 23, 2018
    Date of Patent: March 23, 2021
    Assignee: ASTRAZENECA AB
    Inventor: Kishore Kumar
  • Patent number: 10954211
    Abstract: The present invention provides a compound of a formula (I): or a pharmaceutically acceptable salt thereof; a process for preparing such a compound; and to the use of such a compound in the treatment of an ENaC mediated disease state (such as asthma, CF or COPD).
    Type: Grant
    Filed: May 10, 2019
    Date of Patent: March 23, 2021
    Assignee: ASTRAZENECA AB
    Inventors: Susanne Elisabeth Berglund, Stephen Connolly, Martin Hemmerling, Nafizal Hossain, Anna Kristoffersson, Johan Rune Michael Lundkvist, Grigorios Nikitidis, Lena Elisabeth Ripa, Igor Shamovsky
  • Patent number: 10947559
    Abstract: The present disclosure is directed, in some embodiments, to compositions and methods for inducible modification of a cell genome.
    Type: Grant
    Filed: October 14, 2016
    Date of Patent: March 16, 2021
    Assignee: ASTRAZENECA AB
    Inventors: Marcello Maresca, Mohammad Bohlooly-Yeganeh, Himjyot Jaiswal, Lorenz M. Mayr, Xiufeng Xu
  • Publication number: 20210069215
    Abstract: The invention relates to a formulation comprising formoterol and budesonide for use in the treatment of respiratory diseases. The composition further contains HFA 227, PVP and PEG, preferably PVP K25 and PEG 1000.
    Type: Application
    Filed: March 27, 2020
    Publication date: March 11, 2021
    Applicant: AstraZeneca AB
    Inventors: Nayna Govind, Maria Marlow
  • Publication number: 20210047312
    Abstract: There are disclosed certain novel compounds (including pharmaceutically acceptable salts thereof), that inhibit phosphatidylinositol 3-kinase gamma (PI3K?) activity, to their utility in treating and/or preventing clinical conditions including respiratory diseases, such as asthma and chronic obstructive pulmonary disease (COPD), to their use in therapy, to pharmaceutical compositions containing them and to processes for preparing such compounds.
    Type: Application
    Filed: November 4, 2020
    Publication date: February 18, 2021
    Applicant: AstraZeneca AB
    Inventors: Mickael MOGEMARK, Nils PEMBERTON, Jens PETERSEN, Matthew PERRY, Konstantinos KARABELAS, Pavol ZLATOIDSKY, Rhona COX, Christian TYRCHAN
  • Patent number: 10894789
    Abstract: The present application relates to certain halo-substituted piperidine compounds, pharmaceutical compositions containing them, and methods of using them, including methods for treating substance addiction, panic disorder, anxiety, post-traumatic stress disorder, pain, depression, seasonal affective disorder, an eating disorder, or hypertension.
    Type: Grant
    Filed: February 10, 2017
    Date of Patent: January 19, 2021
    Assignees: ASTRAZENECA AB, EOLAS THERAPEUTICS, INC.
    Inventors: Theodore M. Kamenecka, Jörg Holenz, Steven Wesolowski, Yuanjun He, Roland Bürli
  • Patent number: 10889594
    Abstract: Disclosed is a compound which is 17-chloro-5,13,14,22-tetramethyl-28-oxa-2,9-dithia-5,6,12,13,22-pentaazaheptacyclo[27.7.1.14,7.011,15,016,21.020,24.030,35]octatriaconta-1(37),4(38),6,11,14,16,18,20,23,29,31,33,35-tridecaene-23-carboxylic acid (Formula I) and enantiomers and pharmaceutically acceptable salts thereof. Also disclosed are pharmaceutical compositions of 17-chloro-5,13,14,22-tetramethyl-28-oxa-2,9-dithia-5,6,12,13,22-pentaazaheptacyclo[27.7.1.14,7.011,15.016,21.020,24.030,35]octatriaconta-1(37),4(38),6,11,14,16,18,20,23,29,31,33,35-tridecaene-23-carboxylic acid, and enantiomers and pharmaceutically acceptable salts thereof, and methods of treating cancer with such compounds and compositions.
    Type: Grant
    Filed: December 18, 2018
    Date of Patent: January 12, 2021
    Assignee: AstraZeneca AB
    Inventors: Alexander Hird, Wenzhan Yang, Daniel Robbins, Steven Kazmirski, Dedong Wu, Bo Peng, Jeffrey Johannes, Michelle Lamb, Qing Ye, Xiaolan Zheng
  • Patent number: 10888624
    Abstract: Disclosed are dendrimers of formula (I): and pharmaceutically acceptable salts thereof. Also disclosed are pharmaceutical compositions comprising the dendrimer of formula (I) and methods of using the same for treating cancer.
    Type: Grant
    Filed: April 5, 2019
    Date of Patent: January 12, 2021
    Assignee: ASTRAZENECA AB
    Inventors: Marianne Bernice Ashford, Iain Grant, Edward John Hennessy, William McCoull, Michael Giannis, Brian Kelly, David Owen, John Paul Secrist
  • Patent number: 10882858
    Abstract: The specification generally relates to compounds of Formula (I): and pharmaceutically acceptable salts thereof, where R1, R2, R3, R4 and R5 have any of the meanings defined herein. The specification also relates to the use of compounds of Formula (I) and salts thereof to treat or prevent ATM mediated disease, including cancer. The specification further relates to pharmaceutical compositions comprising to substituted imidazo[4,5-c]quinolin-2-one compounds and pharmaceutically acceptable salts thereof; kits comprising such compounds and salts; methods of manufacture of such compounds and salts; and intermediates useful in such manufacture.
    Type: Grant
    Filed: September 27, 2019
    Date of Patent: January 5, 2021
    Assignee: AstraZeneca AB
    Inventors: Bernard Christophe Barlaam, Kurt Gordon Pike, Andrew John Eatherton, Thomas Anthony Hunt
  • Patent number: 10858355
    Abstract: There are disclosed certain novel compounds (including pharmaceutically acceptable salts thereof), that inhibit phosphatidylinositol 3-kinase gamma (PI3K?) activity, to their utility in treating and/or preventing clinical conditions including respiratory diseases, such as asthma and chronic obstructive pulmonary disease (COPD), to their use in therapy, to pharmaceutical compositions containing them and to processes for preparing such compounds.
    Type: Grant
    Filed: March 9, 2017
    Date of Patent: December 8, 2020
    Assignee: AstraZeneca AB
    Inventors: Mickael Mogemark, Nils Pemberton, Jens Petersen, Matthew Perry, Konstantinos Karabelas, Pavol Zlatoidsky, Rhona Cox, Christian Tyrchan